TIMI 11B

OBJECTIVE: To evaluate the safety and efficacy of subcutaneous enoxaparin compared with unfractionated heparin for the treatment of patients presenting with unstable angina or non-Q-wave myocardial infarction.

View/Download
_______________________________________________________________________________

1. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Antman EM, McCabe CH, Gurfinkel EP, et al. Circulation 1999;100:1593-601.
   | Abstract | Request Reprints |
   

2. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo- controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators. Antman EM. TIMI 11B. Am Heart J 1998;135:S353-60.
   | Request Reprints |
   
   
3. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Antman EM, Cohen M, Radley D, et al. Circulation 1999;100:1602-8.
   | Abstract | Request Reprints |
   
   
4. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. Antman EM, Cohen M, Bernink PJ, et al. JAMA 2000;284:835-42.
   | Abstract | Request Reprints |
   
   
5. Superiority of enoxaparin versus unfractionated heparin for unstable angina/non-Q-wave myocardial infarction regardless of activated partial thromboplastin time. Bozovich GE, Gurfinkel EP, Antman EM, McCabe CH, Mautner B. Am Heart J 2000;140:637-42.
   | Abstract | Request Reprints |
   
   
6. Impact of enoxaparin low molecular weight heparin in patients with Q-wave myocardial infarction. Cohen M, Antman EM, Gurfinkel E, et al. Am J Cardiol 2000;86:553-6, A9.
   | Abstract | Request Reprints |
   
   
7. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. Morrow DA, Antman EM, Tanasijevic M, et al. J Am Coll Cardiol 2000;36:1812-7.
   | Abstract | Request Reprints |
   
   
8. Clinical efficacy of three assays for cardiac troponin I for risk stratification in acute coronary syndromes: a Thrombolysis In Myocardial Infarction (TIMI) 11B Substudy. Morrow DA, Rifai N, Tanasijevic MJ, Wybenga DR, de Lemos JA, Antman EM. Clin Chem 2000;46:453-60.
   | Abstract | Request Reprints |
   
   
9. Enoxaparin in unstable angina/non-ST-segment elevation myocardial infarction: treatment benefits in prespecified subgroups. Cohen M, Antman EM, Gurfinkel EP, Radley D. J Thromb Thrombolysis 2001;12:199-206.
   | Abstract | Request Reprints |
   
   
10. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin? Henry TD, Satran D, Knox LL, Iacarella CL, Laxson DD, Antman EM. Am Heart J 2001;142:590-3.
    | Abstract | Request Reprints |
    
    
11. A simple, readily available method for risk stratification of patients with unstable angina and non-ST elevation myocardial infarction. Holper EM, Antman EM, McCabe CH, et al. Am J Cardiol 2001;87:1008-10; A5.
    | Abstract | Request Reprints |
    
    
12. Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin. Santopinto J, Gurfinkel EP, Torres V, et al. Am Heart J 2001;141:566-72.
    | Abstract | Request Reprints |
    
    
13. Safety and efficacy of unfractionated heparin (UH) versus enoxaparin(E) in obese patients and patients with renal impairment: analysis from ESSENCE and TIMI 11B studies. Inverso SM, Cohen M, Antman EM, Spinler SA, for the ESSENCE and TIMI 11B Investigators. J Am Coll Cardiol 2001; 37(suppl A): 365A
    | Request Reprints |
    
    .
14. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI
    11B and ESSENCE. Antman EM, Cohen M, McCabe C, Goodman SG, Murphy SA, Braunwald E. Eur Heart J 2002;23:308-14.
    | Abstract | Request Reprints |
    
    
15. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Becker RC, Spencer FA, Gibson M, et al. Am Heart J 2002;143:753-9.
    | Abstract | Request Reprints |
    
    
16. Mode and timing of treatment failure (recurrent ischemic events) after hospital admission for non-ST segment elevation acute coronary syndromes. Cohen M, Antman EM, Murphy SA, Radley D. Am Heart J 2002;143:63-9.
    | Abstract | Request Reprints |
    
    
17. Superiority of enoxaparin over unfractionated heparin for the treatment of acute coronary syndromes. Cohen M, Antman EM. Pharmacotherapy 2002;22:542-6; author reply 6-50.
    | Abstract | Request Reprints |
    
    
18. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention. Fox KA, Antman EM, Cohen M, Bigonzi F. Am J Cardiol 2002;90:477-82.
    | Abstract | Request Reprints |
    
    
19. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Omland T, de Lemos JA, Morrow DA, et al. Am J Cardiol 2002;89:463-5. | Abstract | Request Reprints |

     

20. Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. Sabatine MS, McCabe CH, Morrow DA, et al. Am Heart J 2002;143:966-70. .
    | Abstract | Request Reprints |
    
    
21. The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies. de Lemos JA, Morrow DA, Gibson CM, et al. J Am Coll Cardiol 2002;40:238-44.
    | Abstract | Request Reprints |
    
    
22. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM. Am Heart J 2003;146:33-41.
    | Abstract | Request Reprints |
    
    
23. A systematic overview of efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes.Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, Langer A, Blazing MA, Le-Moigne-Amrani A, de Lemos JA, Nessel CC, Harrington RA, Ferguson JJ, Braunwald E, Califf RM. JAMA 2004;292:89-100.
    | Request Reprints |
    
    
24. Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes. Yeh RW, Wiviott SD, Giugliano RP, et al. Am J Cardiol 2007;100:1734-8.
    | Abstract | Request Reprints |